[HTML][HTML] Combination of gefitinib and pemetrexed prevents the acquisition of TKI resistance in NSCLC cell lines carrying EGFR-activating mutation

S La Monica, D Madeddu, M Tiseo, V Vivo… - Journal of Thoracic …, 2016 - Elsevier
Introduction Development of resistance to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors is a clinical issue in patients with epidermal growth factor receptor gene …

Advances in the development of molecularly targeted agents in non-small-cell lung cancer

SO Dolly, DC Collins, R Sundar, S Popat, TA Yap - Drugs, 2017 - Springer
Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the
leading cause of cancer-related mortality. The traditional 'one-size-fits-all'treatment …

The biology, function and clinical implications of exosomes in lung cancer

L Zhou, T Lv, Q Zhang, Q Zhu, P Zhan, S Zhu, J Zhang… - Cancer letters, 2017 - Elsevier
Exosomes are 30–100 nm small membrane vesicles of endocytic origin that are secreted by
all types of cells, and can also be found in various body fluids. Increasing evidence …

[HTML][HTML] Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma

E Bria, S Pilotto, E Amato, M Fassan, S Novello… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung
adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of …

Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials

WX Qi, YJ Sun, Z Shen, Y Yao - Journal of chemotherapy, 2015 - Taylor & Francis
Purpose: To assess the risk of interstitial lung disease (ILD) with epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, and afatinib. Method …

Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations

F Hu, J Xu, B Zhang, C Li, W Nie, P Gu, P Hu… - Clinical Lung Cancer, 2019 - Elsevier
Background For oligometastatic lung adenocarcinoma patients with sensitive epidermal
growth factor receptor (EGFR) mutations, the role of local consolidative therapy (LCT) …

The changing landscape of clinical trial and approval processes in China

Q Zhou, XY Chen, ZM Yang, YL Wu - Nature Reviews Clinical …, 2017 - nature.com
In the past decade, the standards of clinical trials in China have moved closer to
international standards, thus encouraging the development of innovative drugs. However, a …

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies

YL Wu, V Lee, CK Liam, S Lu, K Park, V Srimuninnimit… - Lung Cancer, 2018 - Elsevier
Objective Patients with advanced non-small-cell lung cancer (NSCLC) with an
adenocarcinoma component are recommended to undergo epidermal growth factor receptor …

晚期非小细胞肺癌的药物治疗进展

胡毅, 陶海涛 - 中国药物应用与监测, 2014 - cqvip.com
肺癌目前仍是死亡率较高的恶性肿瘤. 近年来随着分子靶向治疗的进展, 非小细胞肺癌的治疗
已经取得了长足的进步. 许多转化性临床研究结果带来近期疗效, 生活质量尤其是生存的显著 …

[HTML][HTML] Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation

J Dao, PJ Conway, B Subramani… - International journal of …, 2023 - mdpi.com
The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological
marker is being used in clinical trials at every step of clinical management. As ctDNA-based …